Generic drug giant spokesperson says resignation is effective immediately as Desai pursues other opportunities. Source: BioSpace

A look at six biopharma companies that may have major stock catalysts this year. Source: BioSpace

This is a market like the world has never seen. Source: BioSpace

With a trial on hold for more than six months, InVivo has been burning through cash and may not have enough financing to continue operations for much longer. Source: BioSpace

The FDA will establish a council to oversee all animal studies under the agency’s purview. Source: BioSpace

When the debt is repaid next week, Valeant will have reduced its debt by more than $6.7 billion since the end of the first quarter of 2016.. Source: BioSpace

Now insiders say J&J has decided it is no longer interested. Source: BioSpace

The company burned through $1.2B and never brought a drug to market in its 37 years. Source: BioSpace

Based in Toronto, Ontario, Fibrocor Therapeutics was launched in January 2017. Source: BioSpace

The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace